Stockreport

Inhibrx Advances Key Oncology Programs Toward Multiple 2026 Data Readouts [Yahoo! Finance]

Inhibrx, Inc.  (INBX) 
PDF a comprehensive progress update regarding its primary oncology programs. The company is currently advancing two lead therapeutic candidates: INBRX-106, which is a hexava [Read more]